|
||
Tauredon Uses |
||
Progressive juvenile idiopathic arthritis
Child: 1 mg/kg wkly. Max: 50 mg wkly. Calculated initial wkly dose may be preceded by a smaller test dose such as 1/10 or 1/5 of the full dose for 2-3 wk. Continue wkly doses until signs of remission occur then increase dosage intervals to 2 wk. W/ full remission, dosage interval may be increased gradually to 4 wk. If no improvement after 20 wk, dose may be raised slightly or another antirheumatic drug may be tried.
Renal impairment: Severe: Contraindicated.
Hepatic impairment: Severe: Contraindicated.
Active progressive rheumatoid arthritis
Adult: Initially, 10 mg in the 1st wk as test dose, followed by 50 mg wkly until signs of remission occur. Dosage interval is then increased to 2 wk until full remission, then increased gradually to 4-6 wk. May continue for up to 5 yr after complete remission. Discontinue if no major improvement is seen after a total of 1 g (excluding test dose) has been given, or alternatively, in the absence of toxicity, 100 mg may be given wkly for a further 6 wk. Discontinue if there is no sign of remission.
Renal impairment: Severe: Contraindicated.
Hepatic impairment: Severe: Contraindicated.
Tauredon is a gold compound that is used for its immunosuppressive anti-rheumatic effects. Along with an orally-administered gold salt, auranofin, it is one of only two gold compounds currently employed in modern medicine.
Progressive juvenile idiopathic arthritis
Child: 1 mg/kg wkly. Max: 50 mg wkly. Calculated initial wkly dose may be preceded by a smaller test dose such as 1/10 or 1/5 of the full dose for 2-3 wk. Continue wkly doses until signs of remission occur then increase dosage intervals to 2 wk. W/ full remission, dosage interval may be increased gradually to 4 wk. If no improvement after 20 wk, dose may be raised slightly or another antirheumatic drug may be tried.
Renal impairment: Severe: Contraindicated.
Hepatic impairment: Severe: Contraindicated.
Active progressive rheumatoid arthritis
Adult: Initially, 10 mg in the 1st wk as test dose, followed by 50 mg wkly until signs of remission occur. Dosage interval is then increased to 2 wk until full remission, then increased gradually to 4-6 wk. May continue for up to 5 yr after complete remission. Discontinue if no major improvement is seen after a total of 1 g (excluding test dose) has been given, or alternatively, in the absence of toxicity, 100 mg may be given wkly for a further 6 wk. Discontinue if there is no sign of remission.
Renal impairment: Severe: Contraindicated.
Hepatic impairment: Severe: Contraindicated.
Drug Interaction: May increase risk of aspirin-induced liver damage. Increased risk of severe anaphylactoid reaction when used w/ ACE inhibitors.
Potentially Fatal: Increased risk of blood dyscrasias and other severe adverse effects (e.g. proteinuria) when used concomitantly w/ myelossupressive agents, phenylbutazone, penicillamine and antimalarials.
May occur months after therapy is discontinued.
Dermatologic
Dermatitis; pruritus; exfoliative dermatitis; angioedema; chrysiasis (gray-blue skin pigmentation).
EENT
Stomatitis; corneal gold deposition; corneal ulceration; iritis; conjunctivitis; metallic taste. Children: Safety and efficacy in children younger than 6 yr of age have not been established.
GI
Diarrhea; nausea; cholestatic jaundice; ulcerative enterocolitis; GI bleeding; difficulty swallowing; abdominal pain and cramping.
Genitourinary
Nephrotic syndrome or glomerulitis with proteinuria and hematuria.
Hematologic
Anemia; thrombocytopenia; leukopenia; aplastic anemia.
Respiratory
Interstitial pneumonitis; pulmonary fibrosis.
Miscellaneous
Anaphylactoid reactions within minutes of injection, arthralgias for several days after injection, “nitritoid reaction” (eg, vasomotor reaction with flushing, fainting, weakness, dizziness, sweating, nausea, vomiting, malaise and headache).
Exfoliative dermatitis, SLE, necrotising enterocolitis, pulmonary fibrosis. History of haematological disorders, toxicity to heavy metals. Severely debilitated patients. Severe renal or hepatic impairment. Concomitant use w/ antimalarials, immunosuppressive agents, penicillamine or phenylbutazone.
Sodium Aurothiomalate in Czech Republic, Germany, Netherlands, Portugal, Romania, Serbia, Slovakia, Switzerland.
Unit description / dosage (Manufacturer) | Price, USD |
Injectable; Injection; Aurothiomalate Sodium 10 mg | |
Injectable; Injection; Aurothiomalate Sodium 20 mg | |
Injectable; Injection; Aurothiomalate Sodium 50 mg | |
List of Tauredon substitutes (brand and generic names): | |
AUROCRIS (India) | |
10 mg x 5x0.5ml (Samarth) | $ 12.86 |
20 mg x 5x0.5ml (Samarth) | $ 21.90 |
50 mg x 5x0.5ml (Samarth) | $ 33.17 |
AUROCRIS inj 10 mg x 0.5ml (Samarth) | $ 2.57 |
AUROCRIS inj 20 mg x 0.5ml (Samarth) | $ 4.38 |
AUROCRIS inj 50 mg x 0.5ml (Samarth) | $ 6.63 |
Miocrin (Colombia, Singapore, Spain) | |
Miocrin 50 mg/1 mL x 1's (Ifet) | $ 15.00 |
Myocrisin (Australia, Denmark, Finland, Ireland, New Zealand, Sweden, Thailand, United Kingdom) | |
Injectable; Injection; Gold Sodium Thiomalate 2% (sanofi-aventis) | |
Injectable; Injection; Gold Sodium Thiomalate 4% (sanofi-aventis) | |
Injectable; Injection; Gold Sodium Thiomalate 10% (sanofi-aventis) | |
Myocrisin 20 mg x 10's (sanofi-aventis) | |
Myocrisin inj 20 mg 10 x 1's (sanofi-aventis) | |
Myocrisin 10% (United Kingdom) | |
Myocrisin 2% (United Kingdom) | |
Myocrysine (Greece) | |
Shiosol (Japan) | |
Sodium Aurothiomalate (Czech Republic, Germany, Greece, Netherlands, Portugal, Slovakia, Switzerland) | |
Injectable; Injection; Gold Sodium Thiomalate 10 mg / ml | |
Injectable; Injection; Gold Sodium Thiomalate 25 mg / ml | |
Injectable; Injection; Gold Sodium Thiomalate 50 mg / ml | |
Sodium Aurothiomalate Sandoz (Canada) | |
Sodium Bicarbonate Cherubino (Malta) | |
Sodium Bicarbonate P & D (Malta) | |
Tauredon 50mg/0.5ml (Switzerland) |
Users | % | ||
---|---|---|---|
3 month | 1 | 100.0% |
Users | % | ||
---|---|---|---|
> 60 | 2 | 50.0% | |
46-60 | 1 | 25.0% | |
30-45 | 1 | 25.0% |
There are no reviews yet. Be the first to write one! |
Information checked by Dr. Sachin Kumar, MD Pharmacology
|